Comparison of Serum C-Peptide with Peripheral Neuropathy in Type II Diabetes Mellitus

S Kaviprasanna^*

^*Correspondence: S Kaviprasanna, Department of Physiology, Sree Balaji Medical College & Hospital Affiliated to Bharath Institute of Higher Education and Research, India, Email:

Author info »

Introduction

C-peptide is a peptide composed of 31 amino acids. It is released from the pancreatic beta-cells during cleavage process of insulin from proinsulin. Though it's biologically inactive; recent studies suggest that C peptide may improve capillary blood flow in the feet, decrease urinary albumin excretion, and improve nerve function in those individuals with type diabetes mellitus but most commonly in Type I. Hence the study aims to compare the serum C-Peptide levels with Peripheral Neuropathy in patients with Type II Diabetes Mellitus [1-3].

Methodology

Results

From the Table 1 it can be interpreted that the serum CPeptide decreases linearly from Group I to group IV. So group IV with severe or Class 3 Neuropathy has the lowest C-Peptide values whereas those who have no neuropathy in Class O have the highest levels of C-Peptide. From the results it’s inferred that the increasing duration of DM shows decreasing in serum C peptide values also increasing class of neuropathy is sewn when there is an increase in the duration of DM. Increasing Class of Neuropathy 1s associated with decrease in Serum CPeptide levels. Figure 1 shows the comparison of serum cpeptide, duration of diabetes mellitus & neuropathy score among the four groups.

Table 1: Interpretation of C-peptide.

Figure 1: Comparison of serum c-peptide, duration of diabetes mellitus & neuropathy score among the four groups.

Discussion and Conclusion

We have found that the duration of diabetes mellitus is a factor in determining the severity of neuropathy and also in the levels of serum c peptide. Longer the duration, more severe is the class or degree of neuropathy and lesser is the serum C-peptide level. From the nerve conduction study we are able to establish that the patients with no signs or symptoms of neuropathy showed abnormal nerve conduction study, especially in cases that had lowest C peptide had the most severe neuropathy grade. C peptides administered patients of type II DM showed increased nerve conduction velocity and heart rate variability also C peptide improves the metabolic phase of diabetic peripheral neuropathy with effects on na+, k+atpase and improves the structural phase by promoting nerve regeneration [4-10].

References

1. Steiner DF, Cunningham D, Spigelman L, et al. Insulin biosynthesis: evidence for a precursor. Science 1967; 157:697-700.
2. Hills CE, Brunskill NJ. Intellcular signalling by C­peptide. Exp Diabetes Res 2008; :51-58.
3. Sima AA, Zhang W, Sugimoto K et al. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia 2001; 44:889-97.
4. Samnegard B, Jacobson SH, Jaremko G, et al. Effects of C-peptide on glomerular and renal size and renal function 1n diabetic rats. Kidney Int 2001; 60:1258-65.
5. Henriksen JH, Tronier B, Bulow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting non diabetic man. Metabolism l 987; 36:463-68.
6. Zavaroni I, Deferrari G, Lugari R, et al. Renal metabolism of C-peptide in man. J Clin Endocrinol Metabol 1987; 65:494-98.
7. Covic AM, Schelling JR, Constantiner M, et al. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int 2000; 5l:742-50.
8. Gale EA. Latent autoimmune diabetes in         adults. A guide for the perplexed. Diabetologia 2005; 48:2195-99.
9. Thunander M, Torn C, Petersson C, et al. Levels of C-peptide, BMI, and age, and their utility for classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol 2012; 166:1021-29.
10. Redondo MJ, Rodriguez LM, Escalante M, et al. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type I diabetes. Pediatr Diabetes 2012; 13:564-71.